CSPG4 and neoplasm: Collectively, targeting melanoma with CSPG4-CAR-T cells in conjunction with BRAFi/MEKi might reveal synergistic effects on tumor regression and reduce the frequency of CSPG4 down-regulation by simultaneously engaging two important oncogenic drivers.